Wedbush Forecasts Strong Price Appreciation for argenex (NASDAQ:ARGX) Stock

argenex (NASDAQ:ARGX) had its target price lifted by stock analysts at Wedbush from $880.00 to $1,000.00 in a research note issued to investors on Friday, Marketbeat.com reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective would suggest a potential upside of 10.13% from the company’s current price. Wedbush also issued estimates for argenex’s Q4 2025 earnings at $6.48 EPS, Q1 2026 earnings at $7.36 EPS, Q2 2026 earnings at $8.16 EPS, Q3 2026 earnings at $8.95 EPS, Q4 2026 earnings at $9.60 EPS, FY2026 earnings at $34.10 EPS, FY2027 earnings at $46.09 EPS and FY2028 earnings at $61.81 EPS.

Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of argenex from $830.00 to $925.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Evercore ISI boosted their price objective on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Guggenheim reaffirmed a “buy” rating and set a $1,070.00 price objective on shares of argenex in a research note on Thursday, September 18th. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Finally, HC Wainwright boosted their price target on argenex from $774.00 to $915.00 and gave the company a “buy” rating in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $885.94.

argenex Trading Up 1.8%

ARGX opened at $907.98 on Friday. argenex has a 12 month low of $510.05 and a 12 month high of $914.87. The business’s 50-day moving average price is $799.34 and its 200-day moving average price is $672.62. The company has a market cap of $55.90 billion, a P/E ratio of 38.99, a P/E/G ratio of 0.93 and a beta of 0.45.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. Equities research analysts forecast that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Trading of argenex

Several large investors have recently bought and sold shares of ARGX. Bank of New York Mellon Corp raised its position in shares of argenex by 124.5% in the 1st quarter. Bank of New York Mellon Corp now owns 14,283 shares of the company’s stock worth $8,454,000 after acquiring an additional 7,921 shares in the last quarter. Cerity Partners LLC grew its stake in argenex by 45.3% in the first quarter. Cerity Partners LLC now owns 4,654 shares of the company’s stock worth $2,755,000 after purchasing an additional 1,452 shares during the period. Cullen Frost Bankers Inc. grew its stake in argenex by 95.6% in the first quarter. Cullen Frost Bankers Inc. now owns 133 shares of the company’s stock worth $79,000 after purchasing an additional 65 shares during the period. Morse Asset Management Inc raised its holdings in argenex by 98.0% in the first quarter. Morse Asset Management Inc now owns 495 shares of the company’s stock worth $293,000 after purchasing an additional 245 shares in the last quarter. Finally, Wealth Alliance LLC lifted its position in argenex by 14.9% during the first quarter. Wealth Alliance LLC now owns 757 shares of the company’s stock valued at $448,000 after buying an additional 98 shares during the period. 60.32% of the stock is owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.